Mink Therapeutics (INKT) Proxy Filing summary

Executive summary

• Special Meeting scheduled for January 17, 2025, to vote on a reverse stock split at a 1-for-10 ratio.

• The reverse stock split aims to maintain compliance with Nasdaq's minimum bid price requirement and support stock liquidity.

• If approved, the amendment will be filed promptly, and the split will be effective as soon as practicable.

• No fractional shares will be issued; cash will be paid in lieu of fractions.

• The Board recommends voting in favor of the proposal.

Voting matters and shareholder proposals

• Only one proposal is up for vote: approval of a 1-for-10 reverse stock split.

• Stockholders of record as of December 16, 2024, are eligible to vote.

• Voting can be done online, by phone, mail, or during the virtual meeting.

• Majority of votes cast is required for approval; abstentions and broker non-votes have no effect.

• Stockholder proposals for the 2025 Annual Meeting must comply with SEC rules and company bylaws.

Board of directors and corporate governance

• Proxy solicitation is managed by the Board, with officers and employees assisting without extra compensation.

• Board retains discretionary authority to abandon the reverse split before it becomes effective.